Vivo Bio Tech has dispatched web-links to equity shareholders providing access to its Annual Report for FY26. This communication precedes the company's 39th Annual General Meeting scheduled for September 30, 2026.

The web-links were sent in compliance with Section 136 of the Companies Act, 2013 and Regulation 36(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholders who have not registered their email addresses with the company, Registrar and Transfer Agent (RTA), or Depository Participants received letters containing these links. Physical copies of the annual report are available upon written request.

AGM Agenda and Director Re-Appointments

The upcoming meeting will address ordinary business items, including the adoption of audited financial statements for FY26. Shareholders will vote on the re-appointment of Mr. Kalyan Ram Mangipudi as a director by rotation.

Special business resolutions include the re-appointment of two Whole-time Directors:

• Mr. Sri Kalyan Kompella: Re-appointed for five years from November 3, 2026, to November 2, 2031. His consolidated monthly salary is proposed at ₹2,50,000, with the Board authorized to revise gross salary by up to 50% per annum.
• Dr. Sankaranarayanan Alangudi: Re-appointed for five years from January 6, 2027, to January 5, 2032. Aged 83, his re-appointment requires a special resolution under Section 196(3)(a) of the Companies Act, 2013. His monthly salary is set at ₹1,00,000.

Financial Performance Context

The explanatory statement highlights a shift in financial performance for FY26 compared to the prior year. Total income rose slightly to ₹5,300.93 crore from ₹5,147.74 crore in FY25. However, Profit Before Tax contracted sharply to ₹458.26 crore from ₹908.11 crore. This decline resulted in a net loss of ₹193.61 crore in FY26, reversing the net profit of ₹757.08 crore recorded in FY25.

What the Numbers Show

The divergence between top-line growth and bottom-line performance indicates significant margin compression. While revenue increased, the pre-tax profit fell by nearly half, driven by what the company cites as subdued market demand and intense competition leading to low product pricing. The transition from a substantial profit to a net loss underscores the pressure on profitability despite modest income gains.

Meeting Logistics and Shareholder Updates

Remote e-voting will be available from September 27, 2026, at 9:00 am until September 29, 2026, at 5:00 pm. The cut-off date for shareholding eligibility is September 23, 2026. Members holding shares in physical form or demat mode can vote through the Central Depository Services (India) Limited platform. Physical attendance is not permitted.

Shareholders holding shares in physical form are required to update their KYC details with M/s. Aarthi Consultants Private Limited, the company's RTA. Forms such as ISR-1 for PAN/KYC registration and SH-13 for nomination can be downloaded from the company or RTA websites. Demat shareholders should contact their Depository Participants for any KYC updates.

Promoter group entity Maxcell Communication India Private Limited has transferred 12,00,000 equity shares of Vivo Bio Tech Limited off-market on August 21, 2026. The transaction marks the complete exit of the promoter affiliate from the company, reducing its stake to nil.

The disclosure was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Gangireddy Suresh, Director at Maxcell Communication, signed the intimation submitted to the BSE and the listed entity.

Shareholding Changes

Prior to the transfer, Maxcell Communication held 12,00,000 equity shares, representing 5.41% of the total voting capital and 4.09% of the diluted voting capital. The entity had no encumbrances, warrants, or convertible securities associated with this holding.

Following the off-market transfer, the promoter group entity’s holding stands at Nil. There were no changes to the company’s total equity share capital or diluted share capital as a result of this inter-se transfer.

Capital Structure Context

Vivo Bio Tech’s total equity share capital remains at 2,21,90,628 equity shares of ₹10 each, aggregating to ₹22,19,06,280. The total diluted share capital is calculated at 2,93,23,111 equity shares. This diluted figure assumes the conversion of 6,27,409 pending convertible equity warrants and the exercise of 63,22,000 outstanding ESOPs.

What the Numbers Show

The complete divestment by a promoter group entity suggests a consolidation of holdings within the promoter circle or a strategic restructuring of interests. With Maxcell Communication exiting entirely, the voting power previously held by this specific entity is likely consolidated elsewhere within the promoter group, though the filing does not specify the recipient of the transferred shares.